INFLIXIMAB IN TREATMENT OF REFRACTORY JUVENILE ARTHRITIS
Abstract
Inclusion to the clinical practice of genetically engineered biological medications opens new opportunities in treatment of juvenile arthritis. The article summarizes an experience of treatment of juvenile arthritis with infliximab in children’s department of Scientific Center of Rheumatology, Russian Academy of Medical Sciences. The analysis included 55 patients (16 children had systemic type, 23 — polyarticular type of juvenile arthritis, and 16 patients had juvenile spondylarthritis), treated with infliximab in 2002–2009 years. Infliximab was administrated in patients with high activity of the disease refractory to the modern basic therapy. Patients received intravenous infliximab 3–5 mg/kg daily according to the standard scheme (on 0, 2, 6 weeks and further every 8 weeks). Therapy with this drug was estimated as effective (improvement on 30% and more according ACRpedi) in 80% of patients: 16% achieved ACR30, 29% — ACR50, 26% — ACR70, and 9% — ACR90. Unfavorable effects (infusion reactions) were detected in 16% of cases. Infections, including one case of disseminated tuberculosis, developed in 20% of patients. Thus, treatment with infliximab is effective and has good «risk–benefit» ratio in treatment of patients with refractory juvenile arthritis.
Key words: children, juvenile arthritis, infliximab, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):142-149)
About the Authors
I.P. NikishinaRussian Federation
S.R. Rodionovskaya
Russian Federation
A.N. Shapovalenko
Russian Federation
E.S. Fedorov
Russian Federation
D.L. Alekseev
Russian Federation
References
1. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Рук. для врачей, преподавателей, научных сотрудников. Под общ. ред. А.А. Баранова. М.: ВЕДИ. 2007. 308 с.
2. Cassidy J.T., Petty R.E. Textbook of pediatric rheumatology. 4th ed. Philadelphia: WB Saunders. 2001.
3. Szer I.S., Kimura Y., Malleson P.N., Southwood T.R. Arthritis in children and adolescents: Juvenile idiopathic arthritis. Oxford: University press. 456 p.
4. Carrasco R., Smith J.A., Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr. Drugs. 2004; 6: 137–146.
5. Singer N.G., Scalzi L.V. Remittive agents in pediatric rheumatology. Curr. Opin. Rheumatol. 2004; 16: 571–576.
6. Wilkinson N., Jackson G., Gardner–Medwin J. Biologic therapies for juvenile arthritis. Arch. Dis. Child. 2003; 88: 186–191.
7. Алексеева Е.И., Никишина И.П. Ювенильный артрит. В кн. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР–Медиа. 2009. С. 231–270.
8. Ruperto N., Lovell D., Cuttica R. еt al. A randomized placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthr. Rheum. 2001; 56 (9): 3096–3106.
9. Ruperto N., Lovell D., Cuttica R. еt al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an Open-Label treatment extension. Ann. Rheum. Dis. 2009 Apr. 29. doi: 10.1136/ard.2008.100354.
10. Алексеева Е.И., Алексеева А.М., Бзарова Т.М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20–30.
11. Алексеева Е.И., Алексеева А.М., Валиева С.И. и др. Влияние инфликсимаба на динамику функционального класса и рентгенологические изменения хрящевой и костной ткани суставов у больных различными вариантами ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (4): 30–44.
12. Алексеева Е.И., Алексеева А.М., Валиева С.И. и др. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7: 42–54.
13. Алексеева А.М. Эффективность и безопасность блокатора ФНО–альфа – инфликсимаба у больных ювенильным ревматоидным артритом. Автореф. дис. … канд. мед. наук. М. 2008. 19 с.
14. Giannini E.H., Ruperto N., Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40: 1202–1209.
15. Вахлярская С.С., Кондратенко И.В., Бологов А.А. Инфликсимаб в терапии тяжелых форм ювенильного ревматоидного артрита у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2008; 2: 19–21.
16. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
17. Gerloni V., Pontikaki I., Gattinara M., Fantini F. Focus on adverse events of tumor necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long term prospective study of 163 patients. Ann. Rheum. Dis. 2008; 67: 1145–1152.
18. Russo R.A., Katsicas M.M. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with Anti–Tumor Necrosis Factor agents. J. Rheumatol. 2009; 36 (5): 1078-1082
19. Ramanan A.V., Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2003; 30: 401–403.
20. Козлова А.Л., Алексеева Е.И., Валиева С.И. и др. Эффективность инфликсимаба у больных ювенильным анкилозирующим спондилоартритом. Вопросы современной педиатрии. 2009; 8 (2): 20–26.
21. Tse S.M.L., Burgos–Vargas R., Laxer R.M. Anti–Tumor Necrosis Factor Blockade in the Treatment of Juvenile Spondylarthropathy. Artr. Rheuml. 2005; 52 (7): 2103–2108.
22. Saurenmann R.K., Levin A.V., Feldman B.M. et al. Risk of new onset uveitis in patients with juvenile idiopathic arthritis treatment with anti–TNF alpha agent. J. Pediatr. 2006; 149: 833–836.
23. Tynjala P., Lindahl P., Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann. Rheum. Dis. 2007; 66: 548–550.
24. Rabinovic С.Е. Use of Tumor Necrosis Factor Inhibitors in uveitis. Curr. Opin. Rheumatol. 2007; 19 (5): 482–486.
25. Foeldvari I., Nielsen S., Kümmerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007; 34: 1146–1150.
Review
For citations:
Nikishina I., Rodionovskaya S., Shapovalenko A., Fedorov E., Alekseev D. INFLIXIMAB IN TREATMENT OF REFRACTORY JUVENILE ARTHRITIS. Current Pediatrics. 2010;9(1):142-149.
Email this article 
